These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34035281)

  • 21. mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin Deficiency.
    Cao J; An D; Galduroz M; Zhuo J; Liang S; Eybye M; Frassetto A; Kuroda E; Funahashi A; Santana J; Mihai C; Benenato KE; Kumarasinghe ES; Sabnis S; Salerno T; Coughlan K; Miracco EJ; Levy B; Besin G; Schultz J; Lukacs C; Guey L; Finn P; Furukawa T; Giangrande PH; Saheki T; Martini PGV
    Mol Ther; 2019 Jul; 27(7):1242-1251. PubMed ID: 31056400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carbohydrate-response-element-binding protein (ChREBP) and not the liver X receptor α (LXRα) mediates elevated hepatic lipogenic gene expression in a mouse model of glycogen storage disease type 1.
    Grefhorst A; Schreurs M; Oosterveer MH; Cortés VA; Havinga R; Herling AW; Reijngoud DJ; Groen AK; Kuipers F
    Biochem J; 2010 Dec; 432(2):249-54. PubMed ID: 20854262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amnio acid substitution at position 298 of human glucose-6 phosphatase-α significantly impacts its stability in mammalian cells.
    Cao J; Markel A; Hanahoe E; Ketova T; Mihai C; Zalinger Z; Marquardt D; Amato NJ; Cheng YM; Reid DW; Dousis A; Giangrande PH; Schultz JR; Martini PGV; Finn PF
    Amino Acids; 2023 May; 55(5):695-708. PubMed ID: 36944899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia.
    Zhang L; Cho JH; Arnaoutova I; Mansfield BC; Chou JY
    J Inherit Metab Dis; 2019 May; 42(3):470-479. PubMed ID: 30714174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A detailed characterization of the adult mouse model of glycogen storage disease Ia.
    Salganik SV; Weinstein DA; Shupe TD; Salganik M; Pintilie DG; Petersen BE
    Lab Invest; 2009 Sep; 89(9):1032-42. PubMed ID: 19581879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
    Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
    Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector.
    Grinshpun A; Condiotti R; Waddington SN; Peer M; Zeig E; Peretz S; Simerzin A; Chou J; Pann CJ; Giladi H; Galun E
    Mol Ther; 2010 Sep; 18(9):1592-8. PubMed ID: 20571544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia.
    Koeberl DD; Pinto C; Sun B; Li S; Kozink DM; Benjamin DK; Demaster AK; Kruse MA; Vaughn V; Hillman S; Bird A; Jackson M; Brown T; Kishnani PS; Chen YT
    Mol Ther; 2008 Apr; 16(4):665-72. PubMed ID: 18362924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes.
    Chou JY; Jun HS; Mansfield BC
    J Inherit Metab Dis; 2015 May; 38(3):511-9. PubMed ID: 25288127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis of growth failure and partial reversal with gene therapy in murine and canine Glycogen Storage Disease type Ia.
    Brooks ED; Little D; Arumugam R; Sun B; Curtis S; Demaster A; Maranzano M; Jackson MW; Kishnani P; Freemark MS; Koeberl DD
    Mol Genet Metab; 2013 Jun; 109(2):161-70. PubMed ID: 23623482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice.
    Sun MS; Pan CJ; Shieh JJ; Ghosh A; Chen LY; Mansfield BC; Ward JM; Byrne BJ; Chou JY
    Hum Mol Genet; 2002 Sep; 11(18):2155-64. PubMed ID: 12189168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of high- and low-risk hepatocellular adenomas by magnetic resonance imaging in an animal model of glycogen storage disease type 1A.
    Resaz R; Rosa F; Grillo F; Basso L; Segalerba D; Puglisi A; Bosco MC; Mastracci L; Neumaier CE; Varesio L; Eva A
    Dis Model Mech; 2019 Apr; 12(4):. PubMed ID: 30898969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type-1a mouse.
    Lei KJ; Chen H; Pan CJ; Ward JM; Mosinger B; Lee EJ; Westphal H; Mansfield BC; Chou JY
    Nat Genet; 1996 Jun; 13(2):203-9. PubMed ID: 8640227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy.
    Chou JY; Jun HS; Mansfield BC
    Nat Rev Endocrinol; 2010 Dec; 6(12):676-88. PubMed ID: 20975743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case report: Hepatocellular carcinoma in type 1a glycogen storage disease with identification of a glucose-6-phosphatase gene mutation in one family.
    Nakamura T; Ozawa T; Kawasaki T; Yasumi K; Wang DY; Kitagawa M; Takehira Y; Tamakoshi K; Yamada M; Kida H; Sugie H; Nakamura H; Sugimura H
    J Gastroenterol Hepatol; 1999 Jun; 14(6):553-8. PubMed ID: 10385064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Case of Glycogen Storage Disease Type 1a Mimicking Familial Chylomicronemia Syndrome.
    Olgac A; Okur I; Biberoğlu G; Ezgü FS; Tümer L
    Balkan J Med Genet; 2021 Jun; 24(1):103-106. PubMed ID: 34447667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of tumor-promoting pathways implicated in hepatocellular adenoma/carcinoma, a long-term complication of glycogen storage disease type Ia.
    Cho JH; Lee YM; Bae SH; Chou JY
    Biochem Biophys Res Commun; 2020 Jan; 522(1):1-7. PubMed ID: 31735334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.
    Koeberl DD; Sun BD; Damodaran TV; Brown T; Millington DS; Benjamin DK; Bird A; Schneider A; Hillman S; Jackson M; Beaty RM; Chen YT
    Gene Ther; 2006 Sep; 13(17):1281-9. PubMed ID: 16672983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene therapy for glycogen storage diseases.
    Koeberl DD; Koch RL; Lim JA; Brooks ED; Arnson BD; Sun B; Kishnani PS
    J Inherit Metab Dis; 2024 Jan; 47(1):93-118. PubMed ID: 37421310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia.
    Demaster A; Luo X; Curtis S; Williams KD; Landau DJ; Drake EJ; Kozink DM; Bird A; Crane B; Sun F; Pinto CR; Brown TT; Kemper AR; Koeberl DD
    Hum Gene Ther; 2012 Apr; 23(4):407-18. PubMed ID: 22185325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.